2014
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma. Cancer Cell 2014, 26: 682-694. PMID: 25517749, PMCID: PMC4269829, DOI: 10.1016/j.ccell.2014.09.019.Peer-Reviewed Original ResearchMeSH KeywordsAnaplastic Lymphoma KinaseAntineoplastic AgentsCrizotinibDisease-Free SurvivalDrug Resistance, NeoplasmHumansHydrogen BondingInfantKaplan-Meier EstimateKineticsModels, MolecularMolecular Targeted TherapyMutation, MissenseNeuroblastomaOncogenesProtein BindingProtein Kinase InhibitorsPyrazolesPyridinesReceptor Protein-Tyrosine Kinases
2008
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ. Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacology & Therapeutics 2008, 122: 1-8. PMID: 19135477, PMCID: PMC2665203, DOI: 10.1016/j.pharmthera.2008.11.008.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntineoplastic AgentsDrug Delivery SystemsEpidermal Growth FactorErbB ReceptorsHumansLigandsNeoplasmsSignal TransductionConceptsEGF family membersPeptide growth factorsFunctional selectivityGrowth factorErbB family receptorsFamily membersNeck cancerReceptor couplingReceptor tyrosine phosphorylationMalignant phenotypeDivergent biological responsesSame receptorFamily receptorsEGF familyReceptorsErbB receptorsG proteinsCancerCancer chemotherapeuticsCell culturesLigand activityTyrosine phosphorylationColorectalSubsequent differencesBiological responses
2006
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer
Choi SH, Mendrola JM, Lemmon MA. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 2006, 26: 1567-1576. PMID: 16953218, DOI: 10.1038/sj.onc.1209957.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorTyrosine kinase domainKinase domainEGF receptorRecent structural studiesSomatic mutationsCell surface EGF receptorsTyrosine kinase activityAbsence of EGFAutoinhibitory interactionsActivation loopErbB family membersGrowth factor receptorTyrosine phosphorylationEGFR tyrosine kinase domainKinase activityNull backgroundMechanistic basisOncogenic mutationsBiochemical propertiesCell surfaceCell lung carcinoma patientsFactor receptorMutationsLung carcinoma patients